“It’s really important that we don’t think of structures in the brain as monolithic,” said Gowrishankar. “There’s lots of little nuance in brain. How plastic it is. How it’s wired. This finding is showing one way how differences can play out.”
Researchers alter two of five genes responsible for vision in Aedes aegypti to make human targets less visible to these flying insects.
How do you say that again?
Researchers alter two of five genes responsible for vision in Aedes aegypti to make human targets less visible to these flying insects.
New research from the University of Virginia School of Medicine quantifies the antibody response generated by the Pfizer and Moderna COVID vaccines. The findings are some of the earliest to compare the two vaccines’ antibody responses head-to-head. The notable finding was that antibody levels in recipients of the Moderna vaccine were slightly higher than in recipients of Pfizer.
The researchers caution against drawing conclusions about the vaccines’ effectiveness based on the antibody numbers. Both vaccines, they say, have performed exceptionally after having been given to millions of people around the world. The new results are just a small piece in a much larger puzzle as scientists seek to determine if one vaccine may be superior for certain demographics.
“The thing that will be interesting is figuring out if measuring antibody levels ends up being a good marker of vaccine protection,” UVA immunologist Dr. Jeffrey Wilson said. “At the moment, we don’t know for sure.”
The UVA study offers insights into vaccine recipients’ immune response by age.
ASML’s latest EUV lithography machine may be able to kill two birds with one stone! Reviving Moore’s law, the second solving the chip shortage.
The rapid commercialization of space and the establishment of the U.S. Space Force have created ideal conditions for change in the national security space business, says Steve Isakowitz, CEO of the Aerospace Corp. and former president of Virgin Galactic.
Aerospace, based in El Segundo, California, is a federally funded research and development center focused on analysis and assessment of space programs for the Defense Department, NASA and the National Reconnaissance Office.
In an interview with SpaceNews, Isakowitz says unprecedented opportunities are emerging for national security space organizations to capture commercial innovation. Defense programs won’t transform overnight, he says, but change is definitely in the air.
Finding people buried under debris is an extremely dangerous job for first responders. Researchers are building autonomous drones that could help.
A European retailer just leaked Intel’s Alder Lake CPU prices, but Intel’s going to have to back these prices up with performance.
For the newly reported study, Guilak’s team combined these two strategies to generate a new treatment approach for rheumatoid arthritis.
Researchers at Washington University School of Medicine in St. Louis have used CRISPR-Cas9 genome editing to engineer induced pluripotent stem cells (iPSCs) that can be implanted subcutaneously to deliver an anticytokine biologic drug in response to inflammation caused by rheumatoid arthritis. When implanted into a mouse model of rheumatoid arthritis the engineered cells automatically sensed and responded to inflammatory cytokines, and produce therapeutic levels of the drug, which reduced inflammation and also prevented bone erosion.
“Doctors often treat patients who have rheumatoid arthritis with injections or infusions of anti-inflammatory biologic drugs, but those drugs can cause significant side effects when delivered long enough and at high enough doses to have beneficial effects,” said senior investigator Farshid Guilak, PhD, the Mildred B. Simon Professor of Orthopedic Surgery. “We used CRISPR technology to reprogram the genes in stem cells. Then we created a small cartilage implant by seeding the cells on woven scaffolds, and we placed them under the skin of mice. The approach allows those cells to remain in the body for a long time and secrete a drug whenever there is a flare of inflammation.”
Guilak and colleagues report on their studies in Science Advances, in a paper titled, “A genome-engineered bioartificial implant for autoregulated anticytokine drug delivery.”
Juno Solar is one of five projects that SB Energy is building this year, with an additional 1.3 GW scheduled to go online over the next seven months.
From pv magazine USA
Project construction was performed by Signal Energy. SB Energy, along with SOLV, will provide ongoing operations and maintenance services and asset management. First Solar supplied its Series 6 modules and Nextracker supplied its NX Horizon smart solar tracker.
The cashierless technology shift continues apace with today’s news that Zippin has raised $30 million in a series B round of funding. The San Francisco-based company is one of several players in the space to gain traction for a technology that seeks to not only make supermarket queues obsolete, but also generate big data insights for retailers.
Founded in 2,018 Zippin leverages AI, cameras, and smart shelf sensors to enable shoppers to place items in their cart and walk out without waiting. The company opened its first checkout-free store in San Francisco back in 2018, and it has since entered into partnerships with the likes of Aramark, Sberbank, and the Sacramento Kings’ Golden 1 Center to power cashierless stores globally.
Zippin had previously raised around $15 million, and with another $30 million from SAP, Maven Ventures, Evolv Ventures, and OurCrowd, the company is well-financed to capitalize on the retail industry’s continued push toward automation-powered efficiency. The company said its ultimate goal is to retrofit stores with the required technology inside a day, with minimal downtime for retailers.
